Updated: March 24, 2021
Emerging Therapy Solutions® provides access to contracted hospitals or facilities that offer condition-specific evaluations necessary to determine the appropriate procedures and therapies, and the associated services and supplies, that are required for the treatment of complex conditions.
Below is a general ETS therapies services list of the US Food and Drug Administration (FDA) approved cell and gene therapies with conditions pertinent to those therapies, along with transplant and implant services.
NOTE: This list is subject to change with the availability of new therapies and medical innovations.
Breyanzi® (lisocabtagene maraleucel)1
For relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma, and follicular lymphoma grade 3B
For relapsed or refractory acute lymphoblastic leukemia up to age 25, and for adult relapsed or refractory diffuse large B-cell lymphoma
Tecartus™ (brexucabtagene autoleucel)3
For relapsed or refractory mantle cell lymphoma
Yescarta® (axicabtagene ciloleucel)4
For relapsed or refractory B-cell non-Hodgkin’s lymphoma
Luxturna® (voretigene neparvovec)5
For biallelic RPE65 gene mutation
Zolgensma® (onasemnogene abeparvovec-xioi)6
For spinal muscular atrophy
Auto Islet Cell Infusion
Small Bowel Transplant
Lung or Double Lung Transplant
Mechanical Circulatory Support (VAD†, Total Heart) Implant
Autologous (HCT‡) Transplant
Allogeneic (Related or Unrelated HCT) Transplant
To learn more about these therapies or to submit a referral, please call us at 877.455.4822 or email us at email@example.com.
1 https://www. https://packageinserts.bms.com/pi/pi_breyanzi.pdf